Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study
07 juil. 2022 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, July 07, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage Canadian...
Codiak Initiates Patient Dosing in Phase 1 Clinical Trial of exoASO™-STAT6 in Patients with Advanced Hepatocellular Carcinoma, Liver Metastases from Primary Gastric Cancer and Colorectal Cancer
29 juin 2022 08h00 HE
|
Codiak BioSciences, Inc.
exoASO-STAT6 is the third engineered exosome candidate generated from Codiak’s engEx® Platform to enter clinical development CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Codiak...
Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study
19 nov. 2021 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) a clinical stage pharmaceutical...
Privo Technologies, Inc. Announces Positive Results From Phase 1/2 Clinical Trial for PRV111 in Head and Neck Squamous Cell Carcinoma
22 oct. 2021 13h39 HE
|
Privo Technologies
PEABODY, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Privo Technologies, Inc. ("Privo"), announced today the positive results of their Phase 1/2 clinical trial examining their lead asset PRV111 in...
Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study
13 oct. 2021 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors
17 sept. 2021 07h30 HE
|
TCR2 Therapeutics
- Clinical activity observed in all three mesothelin-expressing tumor types treated - Gavo-cel disease control rate (DCR) 81% with tumor regression in 15 of 16 evaluable patients - Overall...
Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021
03 août 2021 00h05 HE
|
Angion Biomedica Corp.
ANG-3070 was well-tolerated across dose cohorts, achieving drug exposures in humans exceeding exposures in which activity was demonstrated in animal models of proteinuric kidney...
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trials for STI-2020 (COVI-AMG) in Healthy Volunteers and in Newly Diagnosed COVID-19 Patients
09 déc. 2020 09h00 HE
|
Sorrento Therapeutics, Inc.
FDA has granted clearance for the commencement of Phase 1 clinical trials of STI-2020 (COVI-AMGTM) in healthy volunteers and COVID-19 patients with mild symptoms.STI-2020, a monoclonal antibody, has...
Sorrento Releases Positive Results of Phase 1B Trial of Resiniferatoxin (RTX) In Reduction of OsteoArthritis (OA) Knee Pain
28 sept. 2020 09h00 HE
|
Sorrento Therapeutics, Inc.
Phase 1b safety data at 6 month post-administration and Day 84 efficacy data available for all patients enrolled.No dose limiting toxicities at any of the doses tested (up to 30 ug) at 6 months...
Sorrento Therapeutics Releases Positive Results of Phase 1B Trial of Resiniferatoxin (RTX) Epidural in Cancer Patients with Reported Intractable Pain
22 sept. 2020 14h30 HE
|
Sorrento Therapeutics, Inc.
Seventeen subjects with advanced cancer pain received epidural RTX (0.4 to 25 mcg).No dose limiting toxicities were reported.A majority of patients reported meaningful pain reduction of 30% or more...